Glenmark Life Sciences Limited Stock

Equities

GLS

INE03Q201024

Pharmaceuticals

End-of-day quote NSE India S.E. 06:00:00 2024-05-06 pm EDT 5-day change 1st Jan Change
830.1 INR -0.10% Intraday chart for Glenmark Life Sciences Limited +0.14% +26.34%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2024 22.83B 274M Sales 2025 * 25.79B 309M Capitalization 102B 1.22B
Net income 2024 4.71B 56.41M Net income 2025 * 5.5B 65.94M EV / Sales 2024 4.17 x
Net cash position 2024 * 3.5B 41.91M Net cash position 2025 * - 0 EV / Sales 2025 * 3.94 x
P/E ratio 2024
20.2 x
P/E ratio 2025 *
18.5 x
Employees 1,824
Yield 2024 *
2.54%
Yield 2025 *
2.9%
Free-Float 15.72%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Glenmark Life Sciences Limited

1 day-0.10%
1 week+0.14%
Current month+0.14%
1 month+1.57%
3 months-6.13%
6 months+33.78%
Current year+26.34%
More quotes
1 week
818.00
Extreme 818
848.00
1 month
743.85
Extreme 743.85
866.00
Current year
655.65
Extreme 655.65
906.00
1 year
513.10
Extreme 513.1
906.00
3 years
370.00
Extreme 370
906.00
5 years
370.00
Extreme 370
906.00
10 years
370.00
Extreme 370
906.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 19-08-12
Director of Finance/CFO - 22-05-31
Compliance Officer - 21-02-22
Members of the board TitleAgeSince
Director/Board Member 66 20-10-29
Chief Executive Officer 58 19-08-12
Human Resources Officer 49 18-10-10
More insiders
Date Price Change Volume
24-05-07 830.1 -0.10% 73,684
24-05-06 831 +0.12% 87,052
24-05-03 830 -1.33% 77,779
24-05-02 841.2 +1.48% 230,238
24-04-30 828.9 +1.18% 133,469

End-of-day quote NSE India S.E., May 06, 2024

More quotes
Glenmark Life Sciences Limited is an India-based company that is primarily engaged in the business of development, manufacture and marketing of active pharmaceutical ingredients (API). The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Company’s products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Company’s research and development facilities are located at Mahape, Ankleshwar and Dahej in India and manufacturing facilities are located at Ankleshwar, Dahej, Mohol and Kurkumbh.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
830.1 INR
Average target price
905.8 INR
Spread / Average Target
+9.11%
Consensus

Quarterly revenue - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW